Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib plus platinum-pemetrexed for symptomatic brain metastases in EGFR-mutant NSCLC
jRCTs071260007Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by AstraZeneca. Primary endpoint: 2-year progression-free survival rate. Started Apr 2026; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on jRCTs071260007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071260007.